@article{d96ac72412094d22b9e483247cdaa07f,
title = "Multi-Parametric Radiomic Model to Predict 1p/19q Co-Deletion in Patients with IDH-1 Mutant Glioma: Added Value to the T2-FLAIR Mismatch Sign",
abstract = "Purpose: The T2-FLAIR mismatch sign has shown promise in determining IDH mutant 1p/19q non-co-deleted gliomas with a high specificity and modest sensitivity. To develop a multi-parametric radiomic model using MRI to predict 1p/19q co-deletion status in patients with newly diagnosed IDH1 mutant glioma and to perform a comparative analysis to T2-FLAIR mismatch sign+. Methods: In this retrospective study, patients with diagnosis of IDH1 mutant gliomas with known 1p/19q status who had preoperative MRI were included. T2-FLAIR mismatch was evaluated independently by two board-certified neuroradiologists. Texture features were extracted from glioma segmentation of FLAIR images. eXtremeGradient Boosting (XGboost) classifiers were used for model development. Leave-one-out-cross-validation (LOOCV) and external validation performances were reported for both the training and external validation sets. Results: A total of 103 patients were included for model development and 18 patients for external testing validation. The diagnostic performance (sensitivity/specificity/accuracy) in the determination of the 1p/19q co-deletion status was 59%/83%/67% (training) and 62.5%/70.0%/66.3% (testing) for the T2-FLAIR mismatch sign. This was significantly improved (p = 0.04) using the radiomics model to 77.9%/82.8%/80.3% (training) and 87.5%/89.9%/88.8% (testing), respectively. The addition of radiomics as a computer-assisted tool resulted in significant (p = 0.02) improvement in the performance of the neuroradiologist with 13 additional corrected cases in comparison to just using the T2-FLAIR mismatch sign. Conclusion: The proposed radiomic model provides much needed sensitivity to the highly specific T2-FLAIR mismatch sign in the determination of the 1p/19q non-co-deletion status and improves the overall diagnostic performance of neuroradiologists when used as an assistive tool.",
keywords = "1p/19q co-deletion, T2-FLAIR mismatch, deep learning, diffuse glioma, radiogenomic",
author = "Shingo Kihira and Ahrya Derakhshani and Michael Leung and Keon Mahmoudi and Adam Bauer and Haoyue Zhang and Jennifer Polson and Corey Arnold and Tsankova, {Nadejda M.} and Adilia Hormigo and Banafsheh Salehi and Nancy Pham and Ellingson, {Benjamin M.} and Cloughesy, {Timothy F.} and Kambiz Nael",
note = "Funding Information: K.N: Olea Medical Advisory Board. T.F.C: cofounder, major stock holder, consultant, and board member of Katmai Pharmaceuticals; member of the board and paid consultant for the 501c3 Global Coalition for Adaptive Research; holds stock in Chimerix and receives milestone payments and possible future royalties; member of the scientific advisory board for Break Through Cancer; member of the scientific advisory board for Cure Brain Cancer Foundation; has provided paid consulting services to Sagimet, Clinical Care Options, Ideology Health, Servier, Jubilant, Immvira, Gan & Lee, BrainStorm, Katmai, Sapience, Inovio, Vigeo Therapeutics, DNATrix, Tyme, SDP, Novartis, Roche, Kintara, Bayer, Merck, Boehinger Ingelheim, VBL, Amgen, Kiyatec, Odonate Therapeutics QED, Medefield, Pascal Biosciences, Bayer, Tocagen, Karyopharm, GW Pharma, Abbvie, VBI, Deciphera, VBL, Agios, Genocea, Celgene, Puma, Lilly, BMS, Cortice, Wellcome Trust, Novocure, Novogen, Boston Biomedical, Sunovion, Human Longevity, Insys, ProNai, Pfizer, Notable labs, Medqia Trizel, and Medscape; and has contracts with UCLA for the Brain Tumor Program with Oncovir, Merck, Oncoceutics, Novartis, Amgen, Abbvie, DNAtrix, Beigene, BMS, AstraZeneca, Kazia, Agios, Boston Biomedical, Deciphera, Tocagen, Orbus, AstraZenica, and Karyopharm. The Regents of the University of California (T.F.C.{\textquoteright}s employer) have licensed intellectual property co-invented by T.F.C. to Katmai Pharmaceuticals. B.M.E: a consultant for Medicenna, MedQIA, Servier, Siemens, Janssen Pharmaceuticals, Kazia, Chimerix, Sumitomo Dainippon Pharma Oncology, ImmunoGenesis, Ellipses Pharma, Monteris, Global Coalition for Adaptive Research, Neosoma, Alpheus Medical, Curtana Pharma, Saimet Biosciences, and Sapience Therapeutics. He also receives grant support from Siemens and Janssen. None for others. Publisher Copyright: {\textcopyright} 2023 by the authors.",
year = "2023",
month = feb,
doi = "10.3390/cancers15041037",
language = "English",
volume = "15",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "4",
}